A Stronger, More Unified Voice to Fight GI Cancers

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

This week on the “CURE® Talks Cancer” podcast, we spoke with Martha Raymond, of The Raymond Foundation, about how providers can ensure patient safety to increase trial enrollment during the COVID-19 pandemic, and what she and her colleagues are doing to provide better trial access to all patients with cancer.

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.